Lineage Announces Appointment of Anula Jayasuriya, M.D., PH.D., M.B.A., to Board of Directors
Lineage Cell Therapeutics (LCTX) appointed Anula Jayasuriya, M.D., Ph.D., M.B.A., to its Board of Directors effective May 4, 2021. Dr. Jayasuriya brings extensive expertise as a healthcare investment executive and venture capitalist, with a focus on women's health. She founded EXXclaim Capital and co-founded the Evolvence India Life Science Fund. The appointment is aimed at enhancing the board's diverse expertise as Lineage pursues advancements in cell therapy and regenerative medicine with potential multi-billion-dollar market opportunities.
- Anula Jayasuriya's appointment may bring fresh insights and expertise, potentially benefiting LCTX's strategic initiatives.
- Dr. Jayasuriya's experience in healthcare investment could enhance LCTX's capabilities in fundraising and partnership opportunities.
- Dr. Jayasuriya's unfamiliarity with Lineage may pose a challenge in understanding the company's specific operational dynamics.
- The transition period may lead to temporary disruptions in board continuity and decision-making.
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell transplants for serious medical conditions, today announced the appointment of Anula Jayasuriya, M.D., Ph.D., M.B.A., to the Company’s Board of Directors, effective as of May 4, 2021. Dr. Jayasuriya is a successful healthcare private equity executive and venture capitalist with extensive clinical, industry, entrepreneurial, and investment experience. Dr. Jayasuriya is the Founder & Managing Director of EXXclaim Capital, an early-stage venture fund focused on catalyzing innovation, entrepreneurship and investment in Women’s Health, and a Co-founder of Evolvence India Life Science Fund (EILSF), the first fund in India to focus exclusively on healthcare and invest in Indian pharmaceutical, biotechnology, medical device and contract services companies. Dr. Jayasuriya received a B.A. from Harvard University summa cum laude, a M. Phil. in pharmacology from the University of Cambridge, an M.D. and Ph.D. (in Microbiology and Molecular Genetics) from Harvard Medical School and an M.B.A. with distinction from Harvard Business School.
“Dr. Jayasuriya is a successful healthcare investment executive with deep insights and experience in the clinical development of a wide range of medical products. We are delighted she will be joining our Board of Directors,” stated Al Kingsley, Lineage’s Chairman of the Board. “Dr. Jayasuriya’s appointment reflects an overall commitment to ensuring that our Board reflects a broad range of expertise and perspectives as Lineage works to position itself as a leader in the field of cell therapy and regenerative medicine.”
“I am excited to join Lineage’s Board at a transformational time in the Company’s history,” stated Dr. Jayasuriya. “Lineage is pioneering a new branch of medicine by advancing its off-the-shelf cell transplant therapies toward later stage clinical trials. These products have the potential to address multi-billion-dollar market opportunities and greatly improve the lives of patients. I look forward to helping the Company as it positions itself for success in 2021 and beyond.”
Anula Jayasuriya, M.D., Ph.D., M.B.A.
Dr. Jayasuriya is the Founder & Managing Director of EXXclaim Capital, an early-stage venture fund focused on catalyzing innovation, entrepreneurship and investment in Women’s Health, and a Co-founder of Evolvence India Life Science Fund (EILSF), the very first fund in India to focus exclusively on health care and invest in Indian pharmaceutical, biotechnology, medical device and contract services companies. Dr. Jayasuriya has applied deep business, scientific, and medical knowledge in her career as a pharmaceutical company executive, private equity executive, and venture capitalist, providing her with a broad experience base spanning clinical, executive, entrepreneurial, and financial roles. She was among the first investors to recognize the untapped opportunity in the unmet needs in women’s health.
Integrating her passion with her investing expertise, in 2013 Dr. Jayasuriya founded EXXclaim Capital, which has invested in a portfolio of diverse Women’s Health companies ranging from digital health, medical devices, and diagnostics to consumer products. EXXclaim’s first investment, nVision Medical, was acquired in 2018 by Boston Scientific Inc. In 2006, she co-founded EILSF, focusing exclusively on investment in Indian pharmaceutical, biotechnology, medical device and contract services companies. Dr. Jayasuriya was previously a partner with Skyline Ventures in Palo Alto, and prior to that with the German/US venture capital firm TVM, in San Francisco. Her prior positions include VP Business Development at Genomics Collaborative Inc., Vice President, Global Drug Development at Hoffman-La Roche for opportunistic infections in AIDS and Transplantation, and Director, Outcomes Research at Syntex Laboratories.
Dr. Jayasuriya received a BA from Harvard summa cum laude, and an MD and PhD (in Microbiology and Molecular Genetics) from Harvard Medical School. She interned in Pediatrics at Boston Children’s Hospital and received an MBA with distinction from Harvard Business School. Dr. Jayasuriya also holds a M. Phil. in pharmacology from the University of Cambridge, in England.
About Lineage Cell Therapeutics, Inc.
Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform Lineage d
FAQ
Who is Anula Jayasuriya and what is her role in Lineage Cell Therapeutics?
What experience does Anula Jayasuriya bring to Lineage Cell Therapeutics?
What potential impact does Dr. Jayasuriya's appointment have on LCTX?
When was the appointment of Anula Jayasuriya to the LCTX Board announced?
